Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 1;175(2):196-198.
doi: 10.1001/jamapediatrics.2020.4678.

Characteristics of Youths Treated With Psychotropic Polypharmacy in the United States, 1999 to 2015

Chengchen Zhang  1 , O'Mareen Spence  1 , Gloria Reeves  2 , Susan dosReis  1
Affiliations

Characteristics of Youths Treated With Psychotropic Polypharmacy in the United States, 1999 to 2015

Chengchen Zhang et al. JAMA Pediatr. .

Abstract

This study investigates differences in the characteristics of US youths treated with psychotropic polypharmacy and in the psychotropic classes used in combination.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Spence reported other support from Pharmaceutical Research Manufacturers of America (PhRMA) and the US Food and Drug Administration (FDA) outside the submitted work. Dr Reeves reported grants from the National Institute of Mental Health (NIMH), FDA, PCORI, and SAMHSA during the conduct of the study. Dr dosReis reported other support from GSK and PhRNA and grants from NIMH, the Patient Centered Outcomes Research Institute (PCORI), and the PhRMA Foundation outside the submitted work. Ms Zhang is a Maryland Center of Excellence in Regulatory Science and Innovation (CERSI) Scholar with the FDA. Dr Spence is a recipient of a Maryland CERSI Scholar award from the FDA and is currently a PhRMA Foundation predoctoral fellow in health outcomes. No other disclosures were reported.

Similar articles

See all similar articles

Cited by

References

    1. National Association of State Mental Health Program Directors. Psychiatric polypharmacy. Accessed October 5, 2019. https://www.nasmhpd.org/content/psychiatric-polypharmacy
    1. Soria Saucedo R, Liu X, Hincapie-Castillo JM, Zambrano D, Bussing R, Winterstein AG. Prevalence, time trends, and utilization patterns of psychotropic polypharmacy among pediatric medicaid beneficiaries, 1999-2010. Psychiatr Serv. 2018;69(8):919-926. doi:10.1176/appi.ps.201700260 - DOI - PubMed
    1. Medhekar R, Aparasu R, Bhatara V, et al. . Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Res Social Adm Pharm. 2019;15(4):395-403. doi:10.1016/j.sapharm.2018.06.005 - DOI - PubMed
    1. Pillay J, Boylan K, Carrey N, et al. . First- and second-generation antipsychotics in children and young adults: systematic review update. AHRQ Comparative Effectiveness Reviews. 2017. - PubMed
    1. Dwyer JB, Bloch MH. Antidepressants for pediatric patients. Curr Psychiatr. 2019;18(9):26-42F. - PMC - PubMed

Publication types

Substances